Activity Goals Incidence of Basal Cell Carcinoma (BCC)

Slides:



Advertisements
Similar presentations
Immune therapy in NSCLC Presentation – 劉惠文 Supervisor – 劉俊煌教授.
Advertisements

Basal Cell Nevus Syndrome Daniel Berg M.D., FRCPC Director, Dermatologic Surgery University of Washington.
Patched and Basal Cell Carcinoma Matt Darch. Patched.
NRS 220 Alterations in Cellular Metabolism.  MDS is a group of disorders that is caused by the formation of abnormal cells in the bone marrow which can.
Karl D. Lewis, MD Associate Professor of Medicine University of Colorado Denver Cutaneous Oncology Program Locally Advanced and Metastatic Basal Cell Carcinoma:
Cutaneous Malignancies
By: Ashley Rodriguez, Yara parada, Briana Mendoza, Jackie Hernandez
Basal Cell Carcinoma. Basal Cell Carcinoma Basal Cell Carcinoma.
The Neck Jochen A. Werner Marburg, Germany. The Neck in squamous cell carcinoma (HNSCC) in cancer of unknown primary in skin cancer in salivary gland.
Vulvar Cancer Women’s Hospital,School of Medicine Zhejiang University.
Sorafenib/Nexavar in Desmoid tumors Mrinal Gounder, M.D. Scientific Director, Desmoid Tumor Research Foundation Melanoma and Sarcoma Service, Memorial.
Photodynamic Therapy for Pre-cancerous lesions of the skin Alan Milligan Clinical Nurse Specialist for Non-Melanoma Skin Cancers.
What should patients with BRAF mutant melanoma receive as front line therapy? Antoni Ribas, M.D. Professor of Medicine Professor of Surgery Professor of.
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,
Metastatic Head Neck Cancer and Immunotherapy
0.05 mg/kg, DLI – 24 hours, dose of light – 40 J/cm2
Skin Cancer Diagnoses and Treatments.
Finding the Right Fit: Personalizing Treatment in Metastatic Castration-Resistant Prostate Cancer.
Optical coherence tomography imaging of non-melanoma skin cancer undergoing photodynamic therapy reveals subclinical residual lesions  L. Themstrup, C.A.
A REVIEW AND UPDATE ON THE ANTI-ANGIOGENIC AGENT, ABT-510
Presented By Luca Malorni at 2017 ASCO Annual Meeting
Prognosis of younger patients in non-small cell lung cancer
S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-
Emerging Trends in the Treatment of Advanced Basal Cell Carcinoma
Systemic treatment of advanced cutaneous squamous and basal cell carcinomas.
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
Endocrine Combinations in HR-Positive MBC: The Future Is Now
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
Expanding Horizons in the Clinical Care of ER-Positive, HER2-Negative Metastatic Breast Cancer.
SKIN CANCER.
What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC
Case Studies.
New Patient Journeys in Non-small cell lung cancer
Discussion Outline Cells of the Immune System.
Basal Cell Carcinoma and Patched
Rossi A et al. Proc ASCO 2011;Abstract 8008.
Metastatic Renal Cell Carcinoma
Cancer Stem Cell Therapies in Gastrointestinal Cancers
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update
A Critical Evaluation of Clinical Research Study Designs
Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?
Treatment of Complicated Intra-abdominal Infections
PARP Inhibitors and Cancer: What Do You Need to Know?
nAMD: Switching Therapies - what you need to know
Beyond Statin Therapy.
Program Goals Introduction Case 1: A 44-Year-Old Woman.
Palumbo A et al. Proc ASCO 2011;Abstract 8007.
Treating mRCC After Initial Antiangiogenic Therapy:
Treatment of HR+ Breast Cancer: A Clinical Update
Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.
Evaluating Next-Generation BTK Inhibitors
Immunotherapy for cSCC
Baselga J et al. SABCS 2009;Abstract 45.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.
Program Goals Basal Cell Cancer Basal Cell Cancer: Beyond Surgery.
Cohort Studies (and Skin Cancer) Never Come Alone
How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.
Maintenance Therapy in Advanced Ovarian Cancer
Factor Xa Inhibitors in PAD
Psoriasis & skin cancer
Volume 4, Issue 5, Pages (June 2018)
Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.
The Changing Field of Melanoma: Ipilimumab.
Patient and Clinician Perspectives on Preventive Therapy for Migraine
Tumor Recurrence 5 Years after Treatment of Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma  Mary-Margaret Chren, Eleni Linos, Jeanette S.
CDK4/6 Inhibitors.
Identifying TRK Fusions in Head and Neck Cancer
Presentation transcript:

Activity Goals

Incidence of Basal Cell Carcinoma (BCC)

Standard Therapies: Non-Melanoma Skin Cancer (NMSC)

Risk Factors

Risk Factors (cont)

Prognosis

Demographics

Mohs Micrographic Surgery (MMS)a

The MMS Procedure Description and Illustration

Therapies for BCC

Combined Topical Field Therapies

Photodynamic Therapy (PDT) Procedure

Topical d - ALA

Role of PDT in Management of Basal Cell Nevus Syndrome (BCNS)

BCNS Clinical Criteria

Investigator-Initiated, Randomized, Double-Blinded Trial for 18 months

2 vs 29 New BCCs Per Year

Mechanism of Aberrant Hedgehog Signaling

Aberrant Hedgehog Signaling

Response in Patient With Metastatic Disease

Phase 1 Study of GDC-0449

ERIVANCE Phase 2 for BCC

Mechanisms of Acquired Resistance

Decrease in Tumor Size by IRF in the Metastatic Cohort

Comparison of Hedgehog Inhibitors

IPI-926 Phase 1 Study

Best Curative Therapy

MMS: Disadvantages

Combination Therapies

Radiotherapy

Challenges With Anti-SMO

Conclusions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.